ESC Premium Access

Patients eligible for proprotein convertase subtilisin/kexin type9 inhibitors (pcsk9i) after acute myocardial infarction. The ESC position applied to patients included in the FAST-MI 2015 registry

Congress Presentation

About the speaker

Professor Francois Schiele

Regional University Hospital Jean Minjoz, Besancon (France)
15 presentations
1 follower

6 more presentations in this session

Modulation of ischemic and bleeding risk by peripheral artery disease after an acute coronary syndrome

Speaker: Doctor M. Cespon Fernandez (Brussels, BE)


Impact of severe anemia (hemoglobin <10 g/dl) in the ischemic-bleeding profile during treatment with dual antiplatelet therapy after hospital discharge for acute coronary syndrome

Speaker: Mrs I. Munoz Pousa (Vigo, ES)


Temporal trends in latecomer ST-segment elevation myocardial infarction patients: Insights from the AMIS Plus Registry 1997-2017

Speaker: Doctor M. Roberto (Biel, CH)


Optimal timing of invasive coronary angiography following NSTEMI

Speaker: Doctor T. Mahendiran (Lausanne, CH)


Benefit of modern P2Y12-inhibitors on long-term prognosis in patients with ST-elevation myocardial infarction with and without advanced chronic kidney disease

Speaker: Doctor J. Schmucker (Bremen, DE)


Access the full session

Translational research in acute coronary syndrome registries

Speakers: Professor F. Schiele, Doctor M. Cespon Fernandez, Mrs I. Munoz Pousa, Doctor M. Roberto, Doctor T. Mahendiran...

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb